

Quadri Meningo® Vaccine is a vaccine against cerebrospinal Meningitis caused by Neisseria meningitidis (Groups A, C, Y, W-135) bacteria. Quadri Meningo™ meets the quality standards set by W.H.O. T.R.S. 594 (1976) and 658 (1981), 904 (2002) and the I.P.

Description

Quadri Meningo™ contains 50 mcg polysaccharide antigen of Neisseria meningitidis of each serogroups A, C, Y & W 135 per dose. It has been stabilized with Lactose and is in freeze dried. It appears as white dry powder/ pellet. It contains Thiomerosal as preservative.

Indications

- Hajj and Umrah pilgrims heading to Mecca, Saudi Arabia and travelers to Sub-Saharan Countries.
- Children and person exposed to infected patients.
- Recommended for children above 18 months of age as routine immunization in endemic areas.

Presentation

Quadri Meningo™ is available in single and 10 dose vial glass vial along with diluent.

Dosage and Administration : Reconstitute Quadri Meningo™ with diluent (0.5 ml for one dose, 5 ml for 10 doses) yielding clear solution. Inject 0.5 ml as S/C or I/M injection.

Side Effects : Reaction to vaccination generally consists of localized injection site reaction (Pain, redness). Transient hyperthermia, headache, vomiting in children etc. Paracetamol can be given to reduce reactogenicity if required.

Storage : Store at 2-8 Degree Centigrade in refrigerator. Product is good to use for 24 months from the date of manufacture.

Other Information

W.H.O has recommended use of Quadrivalent Vaccine (containing A, C, Y & W 135 type antigens) in place of bivalent vaccine (containing only A, C type antigens) especially in areas like India where group specific meningococci, causing disease have not been identified.